Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VIGL

Vigil Neuroscience Inc

Dec 01 • 04:00PM ET

3.20

Dollar change +0.02
Percentage change 0.63	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.04	Insider Own	63.86%	Shs Outstand	35.62M	Perf Week	3.23%
Market Cap	114.78M	Forward P/E	-	EPS next Y	-2.35	Insider Trans	0.02%	Shs Float	12.96M	Perf Month	-54.02%
Income	-78.92M	PEG	-	EPS next Q	-0.54	Inst Own	35.32%	Short Float / Ratio	6.25% / 9.48	Perf Quarter	-47.88%
Sales	0.00M	P/S	-	EPS this Y	2.49%	Inst Trans	30.14%	Short Interest	0.81M	Perf Half Y	-68.00%
Book/sh	3.79	P/B	0.85	EPS next Y	-11.75%	ROA	-42.13%	Target Price	19.88	Perf Year	-74.40%
Cash/sh	3.73	P/C	0.86	EPS next 5Y	-	ROE	-46.19%	52W Range	2.85 - 13.10	Perf YTD	-74.40%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-52.96%	52W High	-75.57%	Beta	1.75
Dividend %	-	Quick Ratio	13.79	Sales past 5Y	0.00%	Gross Margin	-	52W Low	12.28%	ATR	0.63
Employees	56	Current Ratio	13.79	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	32.28	Volatility	10.94% 12.92%
Optionable	No	Debt/Eq	0.10	EPS Q/Q	-0.49%	Profit Margin	-	Rel Volume	3.91	Prev Close	3.18
Shortable	Yes	LT Debt/Eq	0.10	Earnings	Nov 07 BMO	Payout	-	Avg Volume	85.50K	Price	3.20
Recom	1.25	SMA20	-35.68%	SMA50	-45.60%	SMA200	-60.60%	Volume	334,425	Change	0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-18-23	Initiated	JMP Securities	Mkt Outperform	$23
Mar-31-23	Initiated	Mizuho	Buy	$15
Sep-16-22	Initiated	Wedbush	Outperform	$19
Aug-29-22	Initiated	H.C. Wainwright	Buy	$24
Feb-01-22	Initiated	Stifel	Buy	$24
Feb-01-22	Initiated	Morgan Stanley	Equal-Weight	$17
Feb-01-22	Initiated	Jefferies	Buy	$20
Feb-01-22	Initiated	Guggenheim	Buy	$23

Nov-22-23 04:05PM	Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire) -9.17%
Nov-16-23 04:05PM	Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE (GlobeNewswire)
Nov-07-23 07:05AM	Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -9.34%
Oct-18-23 09:52AM	Arm initiated, SQM downgraded: Wall Street's top analyst calls (The Fly)
Oct-17-23 07:05AM	Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease (GlobeNewswire) +6.65%
04:01PM	Loading…
Oct-05-23 04:01PM	Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit (GlobeNewswire)
Sep-26-23 07:05AM	Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP (GlobeNewswire)
Sep-11-23 12:00PM	Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting (GlobeNewswire)
Sep-08-23 04:05PM	Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program (GlobeNewswire)
07:05AM	Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-08-23 07:05AM	Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-23 04:05PM	Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer (GlobeNewswire) -8.33%
Jun-01-23 07:00AM	Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference (GlobeNewswire)
May-10-23 07:00AM	Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-09-23 07:00AM	Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors (GlobeNewswire)
08:30AM	Loading…
May-08-23 08:30AM	Vigil Neuroscience (NASDAQ:VIGL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
07:08AM	Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) (GlobeNewswire)
Mar-30-23 07:00AM	Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101 (GlobeNewswire)
Mar-22-23 07:00AM	Vigil Neuroscience to Present at Stifel 2023 CNS Days (GlobeNewswire) +10.82%
Mar-21-23 07:00AM	Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-02-23 04:00PM	Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire)
Jan-03-23 07:00AM	Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-22 04:01PM	Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team (GlobeNewswire)
Dec-14-22 04:01PM	Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP (GlobeNewswire) +6.66%
Nov-29-22 05:23AM	We Think Vigil Neuroscience (NASDAQ:VIGL) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-28-22 07:00AM	Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022 (GlobeNewswire) +11.46%
Nov-10-22 07:00AM	Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -23.86%
Nov-07-22 07:00AM	Vigil Neuroscience to Present at Upcoming Investor Conferences (GlobeNewswire) +10.07%
Nov-02-22 12:43PM	Vigil Neuroscience Touts Positive Healthy Volunteer Data From Lead Program In Rare Neurological Disease (Benzinga) -12.04%
07:00AM	Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP (GlobeNewswire)
07:00AM	Loading…
Nov-01-22 07:00AM	Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP (GlobeNewswire)
Oct-12-22 07:58AM	7 Short-Squeeze Stocks to Buy for Contrarian Investors (InvestorPlace) +37.01%
Sep-14-22 09:55AM	Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know (Zacks)
Sep-01-22 07:00AM	Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-29-22 09:55AM	How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133% (Zacks)
Aug-12-22 09:55AM	Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to Trade (Zacks) +8.34%
07:00AM	Vigil Neuroscience Announces $75 Million Private Placement Financing (GlobeNewswire)
Aug-08-22 07:00AM	Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-22 07:00AM	Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Aug-01-22 07:00AM	Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022 (GlobeNewswire)
Jul-28-22 07:00AM	Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D. (GlobeNewswire)
Jun-09-22 09:58AM	7 No-Brainer Biotech Stocks to Add to Your Buy List (InvestorPlace)
Jun-07-22 07:00AM	Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia (GlobeNewswire) +10.20%
Jun-01-22 07:00AM	Vigil Neuroscience to Present at 2022 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-22 07:00AM	Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-20-22 07:00AM	Vigil Neuroscience Expands Leadership Team and Board of Directors (GlobeNewswire)
Apr-08-22 12:33PM	We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-25-22 06:30AM	Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire) -6.94%
Mar-21-22 07:00AM	Vigil Neuroscience to Present at Stifel 2022 CNS Days (GlobeNewswire) -24.37%
Mar-03-22 04:05PM	Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology Annual Meeting (GlobeNewswire)
Jan-27-22 01:46PM	Wall Street gyrations may thwart deal closings, IPO outlook (American City Business Journals)
05:30AM	New Year, Fresh Stocks: 3 IPOs That Joined the Market in January (Motley Fool)
Jan-11-22 04:01PM	Vigil Neuroscience Announces Closing of Initial Public Offering (GlobeNewswire)
Jan-06-22 11:07PM	Vigil Neuroscience Announces Pricing of Initial Public Offering (GlobeNewswire)

Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Magovcevic-Liebisch Ivana	President and CEO	Nov 20	Buy	3.75	4,000	15,000	207,687	Nov 20 06:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VIGL

Vigil Neuroscience Inc

Upgrade your FINVIZ experience